| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 7 months ago) | |
| US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 7 months ago) | |
|
US8778962 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 1 month ago) | |
|
US8436010 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 1 month ago) | |
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(2 years from now) | |
|
US8410131 (Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(2 years from now) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(4 years from now) | |
Afinitor is owned by Novartis.
Afinitor contains Everolimus.
Afinitor has a total of 7 drug patents out of which 4 drug patents have expired.
Expired drug patents of Afinitor are:
- US8778962
- US8436010
- US8778962*PED
- US8436010*PED
Afinitor was authorised for market use on 30 March, 2009.
Afinitor is available in tablet;oral dosage forms.
Afinitor can be used as treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic, treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib, treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected., treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
The generics of Afinitor are possible to be released after 01 July, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
Market Authorisation Date: 30 March, 2009
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of ...
Dosage: TABLET;ORAL
AFINITOR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic